HIV感染人群结核菌潜伏感染的诊断与预防性治疗现状

摘要/Abstract

摘要： 多个世纪以来，结核（tuberculosis，TB）持续成为全球，特别是发展中国家的一个重要公共卫生问题。20世纪中期抗结核药物的发现使人们认为结核已经得到控制。随着全球结核监测的放松、结核耐药菌株的增多，以及HIV的流行及其与结核的密切关系，最终导致了20世纪80年代结核的复燃，同时也向全球卫生系统和结核控制部门提出了更为严峻的挑战。因此，在HIV/TB双重感染高流行的地区，结核病的预防性治疗已被纳入国家结核病控制规划的议事日程。

梁享生,刘凤仁,叶临湘,. HIV感染人群结核菌潜伏感染的诊断与预防性治疗现状[J]. 中国防痨杂志, 2007, 29(5): 435-439.

参考文献

1 Bucher HC, Griffith LE, Cuyatt GH, et al. Isoniazid prophylaxis for luber-culosis in HIV infection ： a meta-analysis of randomized controlled trails [J]. AIDS, 1999,13:501-508
2 Williams BG, Granich R, Chauhan LS, et al. The impact of HIV/AIDS on the control of tuberculosis in India[J]. PNAS, 2005,102(27); 9619-9624
3 Canwell MF, Binkin NJ. Tuberculosis in Sub-Saharan Africa: a regional assessment of the impact of the human immunodeHciency virus and Na-tional Tuberculosis Control Program Puality[J] . Tuber Lung Dis, 1996,77:220-225
4 Beck JM, Shellito J. Effect of human immunodeficiency Virus on pul-monary host defends[J] , Semin Respir Infec, 1989,4(2) :75-84
5 Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in de-veloping countries:epidemiologies and strategies for prevention[J].Tuber Lung Dis, 1992,73:311-321
6 American llioracic Society，Centers for Disease Control ami Prevention,and Infectious Diseases Society of America. Targeted tuberculin testing and treatment of latent tuberculosis infection[J] . Am J Respir Crit Care Med，2000,161:S221-S247
7 Preveniion and Management of Tuberculosis in HIV infected Patients in Hong Koitg[R].Scientific Committee of the Advisory Council on AIDS.Hong Kong, Apri 1995. Scientific Committee on AIDS, 1994/1995
8 屠德华.结核病与艾滋病[J].实用肺科杂志，1999,1(6):16-17
9 Yun Shen，Ling Shen, Prabhat Sehgal, et al. Clinical Latency and Reacti-vation of AIDS-Related Mycobacterial Infeclion[J].Journal of virology,2004,78(24)：14023-14032
10 Johnson MP, Coberly JS, Clermont HC, et al. Tuberculin skin lest re-activity among adults infected with human immunodeficiency virus[J]. J Infect Dis, 1992,166：194-198
11 Hiransuthikul N, Hanvanich M, Dore CJ，et al. Factors associated with luberculin skin test reactivity among HIV-infected people in Bangkok [J]. Southeast、Asian J Trop Med Public Health 2003,34(4) ：804-809
12 Moreno S, Baraia-Etxaburu J, Bouza K, et al. Risk for developing tu-berculosis among anergic palienis infected with HIV [J]. Ann Intem Med, 1993,119：194-198
13 Richard S. Kornbluth. Skin Test Responses as Predictors of Tuberculous Infection and of Progression in HIV-infected Person [J], Annals of In-ternal Merficine, 1993,119(3) ：241-243
14 Slovis BS, Plitman JDT Haas DW. The Case Against Anei^y Testing as a Routine Adjunct to Tuberculin Skin Testing [J].JAMA , 2000,283：2003-2007
15 Julio C. Delgado，Eunice Y. Tsai, Sok Thim, et al. Antigen-specific and persistent tuberculin anergy in a cohort of pulmonary palienis from rural Camo(iia[J].PNAS,2002,99(11)：7576-7581
16 Gordin FM, Matts JP, Miller C，el al. A conlrolled irail of isoniazid in persons with anergy and human immunodeficiency virus infection who are at risk for tuberculosis[J] N Engl J Med, 1997,337:315-320
17 Webster CT, Gordin FM, Matts JP, et al. Two-stage tuberculin skin testing in individuals with human immunodeficiency virus infection[J].Community Programs for Clinical Research on AIDS. AM J Respir Cril rare Med, 1995,151 (3 Pt 1):805-808
18 Karin Weldingh, Ida Rosenkrands, Limei Meng Okkels, et al. Assessing the Serodiagnustic Potential of 35 Mycobacterium tuberculosis protein and Identification of Four Novel Serological Antigens [J]. Journal of Clinical Microbiology,2005,43(1) :57-65
19 Samanich, KM, Keen MA, Vissa VD,et al. Serodiagnostic potential of culture filtrate antigens of Mycobacterium tuberculosis[J].Clin. Diag.Lab.Immunol，2000，7：662-668
20 Bothamley，GH，Rudd R,et al. Clinical value of the measurement of Mycobacterium tuberculosis specific antibody in pulmonary tuberculosis [J]. Thorax, 1992,47:270-275
21 Monahan IM, Belts J, Banerjee DK, et al. Differential expression of mycobacterial proteins following phagocytosis by macrophages [J].Mi-crobiology ,2001,147：459-471
22 Nuket Desem,Stephen L.Jones.Development of a Human Gamma In-lerferon Enzyme Immunoassay and Comparison with Tuberculin Skin Testing for Detection of Mycobacterium tuherculo?is Infection[J]. Clin Diagn Lab Immunol,1998,5(4)：531-536
23 Pottumarthy S, Morris AJ, Harrison AC, et al. Evaluation of the tuber-culin gamma interferon assay: potentiafjp replace the Manloux akin teat [J]. J Clin Microbiol, 1999,37:3229-3232
24 Kimtira M, Converse PJ, Astemboreki J，et al.Compariaon between a Whole blood inlerferon-gamma release assay and tuberculosis skin testing for the detection of tuberculosis infection among patients at risk for tuber-culosis exposure[J].J Infec Dis, 1999,179： 1297-1300
25 Sorensen AL, Nagai S, Houen C, et al. Purification and characteriza-tion of a low-molecular-mass T-cell antigen sftcreted by Mycobacterium luberculosis[J]. Infection and Immunity, 1995,63 ： 1710-1717
26 Ajit Lalvni, Ansara Palhan, Helen Mcshane,et al. Rapid Detection of Mycobacterium tuberculosis Infection by Enumeration of Antigen-Specific Tcells[j]. Am. J. Crit. Care Med,2001,163(4) :824-828
27 Beck ST, Incite OM , Arruda RS, et al. Humoral response to low molec. Ular weight anligens of Mycobacierium luberculosis by luberculosis pa-tients and contacts[J]. Braz J Med Biol Res ,2005,38(04) :587-596
28 Lalvani A, Brookes R, Wilkinson R, et al. Human cytolytic and inter-feron gamma-secreting CD8+ T lymphocytes specific for Mycobacterium tuberculosist[J]. Proc Natl Acad Sci US A, 1998,95:270-275
29 Homayoun Shams, Stephem E. Weis, Peter Klucar，et al. En2yme-Linked Immunospot and Tuberculin Skin Testing to Detect Intent Tuber-culosis Infeclion[J] . Ajucrican Journal of Respiratory and Critical Care Medicine, 2005,172：11168
30 Chapman Ann LN, Munkanta Mwansa, Wilkinson Katalin A, et al.Rapid deleciion of active and latent tuberculosis infeclion in HIV-positive individuals by enumeration of Mycobacterium tuberculosis-specific T cells[J]. AIDS,2002,16(17)：2285-2293
31 Flemille Ravn，Martin E. Munk，Ase B. Andersen, etal. Prospective Evaluation of a Whole-Blood Test Using Mycobacterium tuberculosis-Specific Antigens ESAT-6 and CFP-10 for Diagnosis of Aclive Tubercu-losis[J]. Clinical and Diagnostic Laboratory Immunology,2005,12(4)：491-496
32 Peter F. Bames. Diagnosing Intent Tuberculosis Infection[J]. Respir Crit Care Med,2001,163(4) ：807-808
33 Lalvani A, Nagvenkar P, Udwadia Z，et al. Enumeration of T cells spe-cific for RD1-encoded antigens suggests a high prevalence of latent My-cobacterium tuberculosis infection in healthy urban Indians[J]. J Infect Dis, 2001,183:469-477
34 Qyugket MA, Mwinga A, Hosp M, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults[J].AIDS,2001,15⑵：215-22
35 David Wilknson.S B Spuire,Paul Gamer. Effect of preventive treatment for tuberculosis in adults infected with HIV: systematic review of random-ized placebo con如lied trails[J] . BMJ, 1998,317:625-629
36 American Thoracic Society. Preventive treatment in tuberculosis: a state-ment by the Committee on Therapy[J]. Am. Rev. Respir. Dis, 1965,91:297-298
37 Comstock GW. How much isoniazid is needed for prevention of tubercu-losis infection[J] . Am J Respir Crit Care Meds2000，161: S221-S247
38 Fape JW, Jean SS ’ Ho JL，et al. Effect of isoniazid prophylaxis on in-cidence of active tuberculosis and progression of HIV infection[J]. La-cent, 1993,342:268-272
39 Holger Sawert,Enrico Girardi，Giorgio Anonucci,et al. Preventive thera-py for tuberculosis in HIV-infected peraons: analysis of policy options based on tuberculin status and CD4 cell count [J] . Arch intern Med,1998,158:2112-2121
40 U.S. Public Health Service, Infections Disease Society of America.2002 Guidelines for preventing opportunistic infections among HIV-in-fected per8on8-2002[R]. MMWR Recomm Rep 2002,51 (RR08)：1-46
41 International Union Against Tuberculosis Committee, on Prophylaxis. Ef-ficacy of various durations of isoniazid preventive therapy for tuberculo-sis: five years of follow-up in the IUAT trail[EB]. Bull. WHO, 1982,60:555-564
42 Sinder,DE Jr., Cams GJ，Koplan JP. Preventive therapy wilh isoni-azid: cost-effectiveness of different durations of therapy [J]. JAMA,1986,255:1579-1583
43 Jordan TJ, Lewitt EM, Montgomery RL, Reichman LB. Isoniazid as preventive therapy in HIV infected intravenous drug abusers [J].JAMA 1991,265:2987-2991
44 Sinder,DE Jr.,Farer LS. Preventive therapy for tuberculosis infection：an intervention in need of improvement[J]. Am. Rev. Respir. Dis，1984,130:355-356
45 Mitchison DA. The action of antituberculosis drugs in short-course chemolherapy[J]. Tubercle 1985,66:219-225
46 Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tubercu-losis undertaken by the British Medical Research Council Tuberculosis Units. 1946-1986，with relevant subsequent publications [J]. Int J Tuberc Lung Dis, 1999,3:S231-S279
47 Jasmer RM, Snyder DC, Chin DP，et al ? Twelve months of isoniazid com-pared with four months of isoniazid and rifampin for persons with radio-graphic evidence of previous tuberculosis ： an outcome and cost-effective-ness analysis[J]. Am J Respir Crit Care Med,2000,162:1648-1652
48 Villarino M, Ridzon R, Weismuller P,Rifampin preventive therapy for tuberculosis infection [J]. Am J Respir Crit Care Med, 1997, 155:1735-1738
49 Khan K, Muennig P, Behta M,et al.Global drug-resistance patterns and the management of latent tuberculosis infection in immigrants to the Unit-ed Stated [J]. N Engl J Med, 2002,347： 1850-1859
50 Gordin F, Ckaisaon R, Matts J, et al. A randomized trial of 2 months of rifampin ( RFP) and pyrazinamide (PZA) versus 12 months of isoniazid (INH) for the prevention of tuberculosis (TB) in HIV-positive (+), PPD + patients (PTS) [Abstract] [R]. 5th Conference on Retorviruses and Opportunistic Infections. Chicago IL, 1998
51 Gordin FM, Chaisson RE, Matls JP, et al. Rifampin and pyrazinamide versus isonia2id for prevention of tuberculosis in HIV-infected persons：An international randomized trail[J]. JAMA,2000,283t 1445-1450
52 Jasmer RM, Saukkonen JJ，Blumberg HM, et al. Short course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infec-tion： a multic?nt?r clinical trial[J] ? Ann Intern Med,2002,137 ：640-647
53 Centers for Disease Control and prevention . Update： fatal and severe liver injuries associated with rifampicin and pyrazinamide for latent tu-berculosis infection f and revisions in American Thoracic Society/CDC recommendations, United Statedy 2001 [J]. Am J Respir Crit Care Med,2001,164:1319-1320
54 Centers for Disease Control and prevention, American Tlioracic Society ?Update: adverse event and revised American Thoracic Society/CDC rec-onnneiidatioii8 against the use of rifampin and Pyrazinamide for treatment of latent Tuberculosis infection-United States, 2003 [R] . MMWR Morb Mortal Wkly Rep,2003,52(31):735-739